NTLA Intellia Therapeutics, Inc.
8-K Current Report
Filed: February 26, 2026
Health Care
In Vitro & In Vivo Diagnostic SubstancesIntellia Therapeutics, Inc. (NTLA) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 2.02: Results of Operations and Financial Condition
AI Filing Analysis8-K
Item 2.02 · Results of Operations and Financial Condition
- • Q4 and full-year 2025 earnings announced Feb 26, 2026; full results in Exhibit 99.1
- • NTLA is a clinical-stage gene editing company — revenue and cash runway are key metrics to watch in the release
Other Intellia Therapeutics, Inc. 8-K Filings
Get deeper insights on Intellia Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.